摘要
目的:探讨腹腔镜下子宫腺肌病病灶切除术联合醋酸亮丙瑞林缓释微球对子宫腺肌病患者术后子宫体积及月经量的影响。方法:选取鹤壁京立医院83例子宫腺肌病患者,按照随机数字表法分组,对照组41例予以单一腹腔镜下子宫腺肌病病灶切除术治疗,观察组42例实施腹腔镜下子宫腺肌病病灶切除术+醋酸亮丙瑞林缓释微球治疗,观察比较两组治疗3个月后子宫体积、月经量及性激素各指标[黄体生成素(LH)、促卵泡生成激素(FSH)、雌二醇(E2)]变化情况,并统计两组痛经程度(VAS)评分。结果:治疗3个月后观察组子宫体积及月经量均小于对照组,差异有统计学意义(P<0.05);观察组治疗3个月后血清LH、FSH、E2水平均小于对照组,差异有统计学意义(P<0.05);治疗3个月后观察组VAS评分低于对照组,差异有统计学意义(P<0.05)。结论:腹腔镜下子宫腺肌病病灶切除术与药物醋酸亮丙瑞林缓释微球联合应用于子宫腺肌病患者,效果较佳,可改善经量及痛经程度,缩小子宫体积,改善性激素水平。
Objective:To investigate the effect of laparoscopic myomectomy combined with leuprolide acetate sustained-releasemicrospheres on postoperative uterine volume and menstrual flow in patients with adenomyosis.Methods:83patients with adenomyosisin our hospital were randomly divided into control group(n=41)and observation group(n=42).The control group was treated withsingle laparoscopic myomectomy,and the observation group underwent laparoscopic adenomyosis resection+leuprolide acetatesustained-release microspheres treatment,the uterine volume,menstrual flow and sex hormone indicators[luteinizing hormone(LH),follicle-stimulating hormone(FSH),estradiol(E2)]at3months after treatment were observed and compared between the two groups,and analyzed dysmenorrhea(VAS)score.Results:After3months of treatment,the uterine volume and menstrual flow of the studygroup were smaller than those in the control group,the difference was statistically significant(P<0.05);Serum LH,FSH,E2levels ofthe study group were lower than the control group after3months of treatment,the difference was statistically significant(P<0.05);TheVAS score of the observation group was lower than that of the control group after3months of treatment,the difference was statisticallysignificant(P<0.05).Conclusion:Treatment of patients with adenomyosis using laparoscopic myomectomy combined with leuprolideacetate sustained-release microspheres gets a significant effect,which can improve the menstrual flow and dysmenorrhea degree,reducethe uterine volume and improve the sex hormones level.
作者
牛晶娟
NIU Jing-juan(Department of Gynaecology, Jingli Hospital of Hebi City, Hebi Henan 458030, China)
出处
《药品评价》
CAS
2017年第13期60-63,共4页
Drug Evaluation
